Drug-Induced p53 Activation Limits Pancreatic Cancer Initiation
Year: 2024
Type: preprint
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease, initiated predominantly by mutations in Kras , which induce acinar-to-ductal metaplasia (ADM) and subsequent formation of precursor lesions, such as pancreatic intraepithelial neoplasia (PanIN). Progression to PDAC is frequently associated with mutations in the tumor suppressor TP53 , presumably via disrupting p53-mediated cellular senescence of PanINs. Whether TP53 also has tumor-suppressive activity in earlier phases of PDAC initiation has been less clear. In this study, we investigate the impact of pharmacological stabilization of the wild-type p53 protein on the formation of ADM in a Kras G12D -driven mouse model of PDAC. Our findings demonstrate that p53 stabilization via Nutlin-3a significantly reduces both ADM and PanIN formation by promoting the differentiation of ADM into acinar cells. This differentiation coincides with p53-dependent upregulation of the transcription factor Mist1 ( Bhlha15 ), a critical inducer of acinar cell identity. Our results reveal a role for p53 in tissue repair and maintenance of homeostasis in tumor suppression and suggest pharmacological engagement of p53 as an intervention strategy to prevent PDAC initiation.
Authors: Jennifer J Twardowski, Thomas I Heist, Zamira Guerra Soares, Emily S Berry, Luis I Ruffolo, Christoph Pröschel, Stephano S Mello
Institution: University of Rochester
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4399276128
